TY - JOUR
T1 - CKAP4 is a Dickkopf1 receptor and is involved in tumor progression
AU - Kimura, Hirokazu
AU - Fumoto, Katsumi
AU - Shojima, Kensaku
AU - Nojima, Satoshi
AU - Osugi, Yoshihito
AU - Tomihara, Hideo
AU - Eguchi, Hidetoshi
AU - Shintani, Yasushi
AU - Endo, Hiroko
AU - Inoue, Masahiro
AU - Doki, Yuichiro
AU - Okumura, Meinoshin
AU - Morii, Eiichi
AU - Kikuchi, Akira
PY - 2016/7/1
Y1 - 2016/7/1
N2 - Dickkopf1 (DKK1) is a secretory protein that antagonizes oncogenic Wnt signaling by binding to the Wnt coreceptor lowdensity lipoprotein receptor-related protein 6 (LRP6). DKK1 may also regulate its own signaling to promote cancer cell proliferation, but the mechanism is not understood. Here, we identified cytoskeleton-associated protein 4 (CKAP4) as a DKK1 receptor and evaluated CKAP4-mediated DKK1 signaling in cancer cell proliferation. We determined that DKK1 binds CKAP4 and LRP6 with similar affinity but interacts with these 2 receptors with different cysteine-rich domains. DKK1 induced internalization of CKAP4 in a clathrin-dependent manner, further supporting CKAP4 as a receptor for DKK1. DKK1/CKAP4 signaling activated AKT by forming a complex between the proline-rich domain of CKAP4 and the Src homology 3 domain of PI3K, resulting in proliferation of normal cells and cancer cells. Expression of DKK1 and CKAP4 was frequent in tumor lesions of human pancreatic and lung cancers, and simultaneous expression of both proteins in patient tumors was negatively correlated with prognosis and relapse-free survival. An anti-CKAP4 antibody blocked the binding of DKK1 to CKAP4, suppressed AKT activity in a human cancer cell line, and attenuated xenograft tumor formation in immunodeficient mice. Together, our results suggest that CKAP4 is a potential therapeutic target for cancers that express both DKK1 and CKAP4.
AB - Dickkopf1 (DKK1) is a secretory protein that antagonizes oncogenic Wnt signaling by binding to the Wnt coreceptor lowdensity lipoprotein receptor-related protein 6 (LRP6). DKK1 may also regulate its own signaling to promote cancer cell proliferation, but the mechanism is not understood. Here, we identified cytoskeleton-associated protein 4 (CKAP4) as a DKK1 receptor and evaluated CKAP4-mediated DKK1 signaling in cancer cell proliferation. We determined that DKK1 binds CKAP4 and LRP6 with similar affinity but interacts with these 2 receptors with different cysteine-rich domains. DKK1 induced internalization of CKAP4 in a clathrin-dependent manner, further supporting CKAP4 as a receptor for DKK1. DKK1/CKAP4 signaling activated AKT by forming a complex between the proline-rich domain of CKAP4 and the Src homology 3 domain of PI3K, resulting in proliferation of normal cells and cancer cells. Expression of DKK1 and CKAP4 was frequent in tumor lesions of human pancreatic and lung cancers, and simultaneous expression of both proteins in patient tumors was negatively correlated with prognosis and relapse-free survival. An anti-CKAP4 antibody blocked the binding of DKK1 to CKAP4, suppressed AKT activity in a human cancer cell line, and attenuated xenograft tumor formation in immunodeficient mice. Together, our results suggest that CKAP4 is a potential therapeutic target for cancers that express both DKK1 and CKAP4.
UR - http://www.scopus.com/inward/record.url?scp=84978372617&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84978372617&partnerID=8YFLogxK
U2 - 10.1172/JCI84658
DO - 10.1172/JCI84658
M3 - Article
C2 - 27322059
AN - SCOPUS:84978372617
SN - 0021-9738
VL - 126
SP - 2689
EP - 2705
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 7
ER -